AAN 2021 – Helios backs Alnylam’s sunny forecasts
Full data from the Helios-A trial support vutrisiran’s profile as a more convenient Onpattro, though that’s probably as good as it gets.
A new market beckons for Alzheimer’s blood tests
If drugs acting on amyloid and tau can defy the sector’s history of failure, the testing landscape will change dramatically.
Sage’s technical tremor win fails to move
Success in a study in essential tremor is marred by a high rate of adverse events and patient dropouts.
Second-quarter catalysts for the smaller players
Key catalysts approach for Orphazyme, Gemini and Immutep.
Drug rejections hold steady in 2020
Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
Prilenia hopes to buck the Huntington’s trend
Prilenia’s pridopidine is the last big late-stage hope in the disorder, but it already failed phase 2, and phase 3 under the name Huntexil.
